Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma

Phase 2 Completed 194 enrolled EyePoint Pharmaceuticals, Inc.

RandomizedParallel-groupTriple-blindTreatment

Summary

This is a phase 2, double masked, randomized, multi-center, parallel-group, 28-day study assessing the safety, tolerability and ocular hypotensive efficacy of AKB-9778 Ophthalmic Solution 4.0% administered once (AM) or twice (AM \& PM) daily when used as an adjunctive therapy to latanoprost ophthalmic solution 0.005% once daily (PM) in subjects with elevated IOP due to OAG or OHT.

Timeline

Start: 2020-06-06
Primary completion: 2020-11-05
Completion: 2020-11-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AKB-9778	Unknown	4 %	Other
Background	Latanoprost	Small molecule	0.005 %	Other

Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma

Summary

Timeline

Drugs

Indications